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ierre-Emmanuel Morange, MD, PHD,† Jean-Philippe Mouret, MD,* Laurent Bali, MD,*
ierre-Julien Moro, MD,* Marc Lambert, MD,* Marie-Christine Alessi, MD, PHD,†
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bjectives The aim of this study was to assess, in clopidogrel nonresponders undergoing elective
ercutaneous coronary intervention (PCI), the beneﬁt of adjusted antiplatelet therapy with glyco-
rotein (GP) IIb/IIIa antagonist administration during PCI for 1-month clinical outcome.
ackground Numerous biological studies have reported interindividual variability in platelet re-
ponse to clopidogrel with clinical relevance, and high post-treatment platelet reactivity (adenosine
iphosphate-induced aggregation 70%) has been proposed to deﬁne nonresponse to clopidogrel.
hese nonresponders might beneﬁt from tailored antiplatelet therapy.
ethods One hundred forty-nine clopidogrel nonresponders referred for elective PCI were prospec-
ively included and randomized to “conventional group” (n  75) or “active group” with GP IIb/IIIa
ntagonist (n  74). All patients received 250-mg aspirin and 600-mg clopidogrel before PCI and
latelet testing.
esults The rate of cardiovascular events at 1 month was signiﬁcantly lower in the “active group”
han in the “conventional group”: 19% (n  14) versus 40% (n  30), p  0.006, odds ratio: 2.8;
5% conﬁdence interval: 1.4 to 6.0. No patient in either group had post-procedural Thrombolysis In
yocardial Infarction major bleeding or required transfusions.
onclusions The present study suggested beneﬁt of tailored antiplatelet therapy during elec-
ive PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding
isk. (J Am Coll Cardiol Intv 2008;1:649–53) © 2008 by the American College of Cardiology
oundation
rom the *Department of Cardiology and †Inserm, U626, Faculté de Médecine, Laboratoire d’Hématologie, CHU Timone,
arseille, France. This work was supported by the Assistance Publique Hôpitaux de Marseille.anuscript received July 3, 2008; revised manuscript received July 29, 2008, accepted August 16, 2008.
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650latelet inhibition with aspirin and clopidogrel has significantly
educed recurrent ischemic events after percutaneous coronary
ntervention (PCI) and/or non–ST-segment elevation acute
oronary syndrome (ACS) (1–3). Nevertheless, ischemic
vents still occur, and low response to clopidogrel therapy could
e a major factor. Numerous biological studies have reported
nterindividual variability in platelet response to clopidogrel
See page 660
ith clinical relevance (4–10). Several strategies have been
roposed to overcome this variability of response, including
igher dose (11), additional loading doses (12), or alternative
herapies such as new P2Y12 receptor inhibitors (13). How-
ver, no study has ever tested the benefit of glycoprotein (GP)
Ib/IIIa antagonist during PCI for clopidogrel nonresponders.
everal platelet tests have been proposed to assess clopidogrel
esponse. Nowadays, adenosine diphosphate-induced platelet
aggregation (ADP-Ag) remains
the gold standard and has been
the most widely correlated with
clinical events in large sample size
studies (7,8). Previous studies
from our group and others pro-
posed a threshold value of
ADP-Ag70% to identify clopi-
dogrel nonresponders with higher
risk of recurrent ischemic events,
including stent thrombosis (ST)
(5,8,11). Therefore, with this cut-
off value, we conducted a prospec-
tive and randomized study to as-
sess the benefit of GP IIb/IIIa
inhibitor administration in clopi-
dogrel nonresponders undergoing
elective PCI.
ethods
tudy population. Patients older than 18 years with stable
ngina or a positive functional study with a planned PCI with
tent implantation of a de novo lesion in a native coronary
rtery were prospectively eligible for inclusion. Exclusion cri-
eria were: left ventricular ejection fraction 30%, acute coro-
ary syndrome in the previous month, prior myocardial infarc-
ion in the target vessel related territory, positive biomarkers
re-PCI, platelet count 100 g/l, and history of bleeding
iathesis. The study protocol was approved by the insti-
utional ethics committee, and patients gave informed
onsent for participation. All the patients were receiving
hronic aspirin therapy (75 mg daily), and none of them
ere receiving chronic clopidogrel therapy. Antiplatelet
herapy was administered with loading doses of 600 mg
bbreviations
nd Acronyms
CS  acute coronary
yndrome
DP-Ag  adenosine
iphosphate-induced platelet
ggregation
V  cardiovascular
P  glycoprotein
CI  percutaneous
oronary intervention
PP  platelet-poor plasma
RP  platelet-rich plasma
T  stent thrombosis
ASP  vasodilator-
timulated phosphoproteinf clopidogrel and 250 mg of aspirin the day before the Irocedure. These loading doses were administrated under
ontrol of a nurse to avoid any problem with compliance.
fter hospital discharge, all the patients identified as
onresponders to clopidogrel received aspirin 75 mg and
lopidogrel 150 mg for at least 1 month.
lood samples and platelet aggregation. Blood samples were
rawn the morning before the procedure, at least 12 h after the
oading dose of clopidogrel and aspirin. Blood was immediately
ollected in a vacutainer tube containing 3.8% trisodium
itrate, filled to capacity, and sent immediately to the hemo-
tasis laboratory. The blood-citrate mixture was centrifuged at
20 g for 5 min. The resulting platelet-rich plasma (PRP) was
ept at room temperature for use within 1 h. The platelet count
as determined in the PRP sample and adjusted to 2.5 108
l–1 with homologous platelet-poor plasma (PPP). Platelets
ere stimulated with ADP (10 mol/l), and aggregation was
ssessed with a PAP4 Aggregometer (Biodata Corporation,
ellcome, Paris, France). Aggregation was expressed as the
aximal percentage change in light transmittance from base-
ine with PPP as reference. Here we report data on maximal
ntensity of platelet aggregation with ADP. The coefficient of
ariation of maximal intensity of platelet aggregation with
DP was 6.5%. The normal ranges obtained from a healthy
opulation are 69% to 104% for ADP-Ag. Nonresponse to
lopidogrel was defined by ADP-Ag 70%, as described
reviously (5,8,11).
rocedure. After assessment of clopidogrel response, clopi-
ogrel nonresponders were randomized 1:1 to the “conven-
ional group” with GP IIb/IIIa antagonists left to the physi-
ian’s discretion according to current guidelines or the “active
roup” with systematic administration of GP IIb/IIIa antago-
ist (Abciximab) (Fig. 1). Patients in the “active” group
eceived abciximab (0.25 mg/kg of body weight bolus, followed
y a 0.125-g/kg/min [maximum, 10 g/min] infusion for
2 h), plus heparin, 50 U/kg of body weight. Patients in the
conventional” group received heparin bolus, 70 U/kg.
nd points. The clinical end point included the following
ardiovascular (CV) events during 1-month follow-up:
eath from any cause, periprocedural myonecrosis, acute or
ubacute definite or probable ST, and recurrent ACS.
ollow-up events were prospectively assessed by clinical
isit. Recurrent ACS was defined by the presence of
ymptoms compatible with recurrent ischemia needing new
ospital stay and coronary angiography. Stent thrombosis
as defined according to the new Academic Research
onsortium definitions. Periprocedural myonecrosis was
efined as post-procedural increase of troponin I higher
han the upper limit of normal (0.4 ng/ml). Drug therapy
ompliance was assessed. Occurrence of major bleeding
ccording to the Thrombolysis In Myocardial Infarction
riteria (14) was reported.
tatistical analysis. Statistical analysis was performed with the
raphpad Prism Software (version 4.00, Graphpad Software,nc., San Diego, California). Continuous variables are ex-
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651ressed as mean  SD. Categorical variables are expressed as
requencies and percentages. Comparisons between the groups
ere made with the chi-square or Fisher exact test for
ategorical variables, and mean levels were compared with the
npaired t test for continuous variables. Data were evaluated
ith an intent-to-treat analysis. We calculated that 130
atients should be included to detect a difference of 50%
etween both groups (alpha 0.05, beta 0.20, statistical power
.80). Patient curves for freedom from death or major adverse
ardiac events were constructed according to Kaplan and
eier. Comparisons were made with the log-rank test. Sta-
istical significance was set at p  0.05.
esults
mong 643 patients scheduled for planned PCI, 149
lopidogrel nonresponders (23%) (ADP-Ag 70%) were
rospectively included and randomized to the “conventional
roup” (n  75) or the “active group” (n  74).
Baseline characteristics of the patients randomized to
oth strategies were similar (Table 1). Two patients (3%) in
he “conventional group” received a GP IIb/IIIa antagonist
uring the procedure. Procedural data were comparable
etween groups (Table 2). The mean time between the
oading dose and blood sampling was 18.3  2.1 h in the
hole population and similar between groups.
Clinical follow-up was performed 1 month after PCI in
ll patients. The rate of CV events was significantly lower in
he “active group” than in the “conventional group”: 19%
n  14) versus 40% (n  30), p  0.006; odds ratio: 2.8;
Figure 1. Design of the Study
Patients admitted for elective coronary stenting included if nonresponder to c
(ADP-Ag) and randomized to either active or conventional strategy. PCI  per5% confidence interval: 1.4 to 6.0 (Fig. 2). During-month follow-up, the CV events were 1 and 0 for death,
and 0 for ST, 2 and 1 for recurrent ACS, and 26 and 13
or periprocedural myonecrosis in the “conventional” and
active” groups, respectively (Fig. 3). No patient in either
grel according to adenosine diphosphate-induced platelet aggregation
ous coronary intervention.
Table 1. Baseline Characteristics Randomized to “Active” or
“Conventional” Strategy
Characteristics
Active
Strategy
(n  74)
Conventional
Strategy
(n  75) p Value
Male 55 (74) 58 (77) 0.71
Age (yrs) 66 9 64 8 0.68
Body mass index (kg/m2) 27 4 28 5 0.82
CV risk factors
Hypertension 48 (65) 45 (60) 0.61
Diabetes mellitus 26 (35) 30 (40) 0.62
Smoker 22 (30) 26 (49) 0.60
Dyslipidemia 54 (74) 57 (76) 0.71
Familial history 14 (19) 18 (24) 0.55
Discharge medications
Statins 60 (81) 62 (83) 0.83
Beta blocker 41 (55) 39 (52) 0.74
ACE inhibitors 33 (45) 36 (48) 0.73
Ejection fraction 62 11 60 14 0.59
Biological data
Creatinine (mg/dl) 97 12 102 21 0.78
CRP (mmol/l) 2.5 0.8 2.7 0.7 0.70
Platelet count 211 33 225 43 0.60
ADP-induced aggregation 78 6 78 7 0.84
Values are mean SD for quantitative variables and n (%) for qualitative variables.
ACE  angiotensin-converting enzyme; ADP  adenosine diphosphate; CRP  C-reactivelopidoprotein; CV cardiovascular.
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652roup had post-procedural Thrombolysis In Myocardial
nfarction major bleeding or required transfusions.
iscussion
he present study suggested benefit of tailored antiplatelet
herapy during elective PCI with GP IIb/IIIa antagonist for
lopidogrel nonresponders.
Numerous biological studies, usually based on ADP-Ag,
ave reported interindividual variability in platelet response
o clopidogrel with clinical relevance (4–8). Recently, a new
ow cytometric vasodilator-stimulated phosphoprotein
VASP) phosphorylation assay has been introduced to
easure specific inhibition of clopidogrel’s biochemical
arget via the P2Y12 receptor. The platelet reactivity index
ASP has been associated with recurrent ischemic events
fter PCI (9) and after non–ST-segment elevation ACS
Table 2. Procedural Characteristics Among Patients Randomized to
“Active” or “Conventional” Strategy
Characteristics
Active
Strategy
(n  74)
Conventional
Strategy
(n  75) p Value
Reference diameter 2.8 0.5 2.6 0.4 0.47
Minimal lumen diameter 1.0 0.3 1.0 0.2 0.27
% stenosis 64 9 66 10 0.38
Residual stenosis, % 11 3 11 3 0.97
Total stent length, mm 24 9 25 7 0.66
Stent diameter, mm 3 0.3 3 0.4 0.83
GP IIb/IIIa antagonists 74 (100) 2 (3) 0.0001
Values are mean SD for quantitative variables and n (%) for qualitative variables.
GP glycoprotein.
p=0.006
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Figure 2. Kaplan-Meier Analysis for 30-Day Clinical Outcome According
to Groupfi
Log-rank  7.5, p  0.006. CV  cardiovascular.10). The remaining question was to define the strategy to
vercome nonresponse to clopidogrel in these high-risk
atients. Several strategies have been proposed to improve
ntithrombotic therapy of these nonresponders. In a well-
onducted study, Bonello et al. (9) proposed additional
oading doses with repeated VASP assay. This strategy was
ssociated with better clinical outcome but required a longer
ospital stay length and deferred PCI. The VASP assay is
robably the most specific platelet test to assess P2Y12
athway inhibition and has been proposed by these authors
o adapt antiplatelet therapy. However, the clinical data
upporting predictive value of the VASP are lower than
DP-Ag and based on small sample-size single-center
tudies (9,10). Moreover, the threshold proposed for this
est has a good sensitivity and negative predictive value but
ery poor specificity or positive predictive value (9,10).
ndeed, these cutoff values identified up to 80% of nonre-
ponders (10), suggesting a need to adapt medications for
ore than one-half of the patients referred to PCI.
hether this test is accurate to identify a high-risk sub-
roup or the cutoff value proposed is discriminative enough
ill have to be addressed. Before wide use of clopidogrel,
P IIb/IIIa antagonists were used in elective PCI. Re-
ently, the ISAR REACT (Intracoronary Stenting and
ntithrombotic Regimen: Rapid Early Action for Coronary
reatment) study suggested that, in patients at low-to-
ntermediate risk who undergo elective PCI after pre-
reatment with a high loading dose of clopidogrel, abcix-
mab was not associated with any clinically measurable
enefit at 30 days (15). In contrast, the ISAR REACT 2
tudy showed that abciximab reduced the risk of adverse
vents in patients with non–ST-segment elevation ACS
ith positive troponin undergoing PCI after pre-treatment
ith 600 mg of clopidogrel (16). The present study identi-
*        *
Death ST ACS PMI CV events
0
10
20
30
40
Active
Conventional
%
Figure 3. Incidence of CV Events According to the Strategy
*p  0.01. ACS  acute coronary syndrome; CV  cardiovascular; PMI 
periprocedural myonecrosis; ST  stent thrombosis.ed another subgroup of patients undergoing PCI who
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653ight benefit from periprocedural abciximab administra-
ion, the clopidogrel nonresponders.
Our findings underline the necessity to optimize the
egree of platelet inhibition at the time of PCI. The
evelopment of new ADP-antagonists could be helpful in
hese clinical settings. Indeed, a multicenter randomized
tudy demonstrated the clinical superiority for ischemic end
oints but with a significant increased bleeding risk (13).
evelopment of these new drugs with more potent, rapid,
nd consistent antiplatelet effects might solve the issue of
clopidogrel resistance” and lead us to shift from antiplatelet
esistance to bleeding risk assessment.
Adjusted antiplatelet therapy based on platelet testing could
e more easily feasible with development of point-of-care
latelet assay usable in daily clinical practice. Indeed, ADP-Ag
nd VASP have been widely used to assess peri-PCI platelet
unction. However, these laboratory tests require experienced
taff, time, and sample preparation. Thus, there is a clinical
eed to have a reliable assay for measuring platelet function
fter antiplatelet therapy for monitoring and potentially tailor-
ng antiplatelet dosing regimens to individual patients. The
artridge-based VerifyNow point-of-care platelet function as-
ay (Accumetrics, San Diego, California) was designed to
vercome the practical limitations of conventional in vitro
aboratory tests of platelet function. This test has been recently
ssociated with recurrent clinical events after elective PCI (17).
hether tailored antiplatelet therapy integrating both ischemic
nd bleeding risks with this point-of-care assay will improve
linical prognosis has to be addressed in randomized trials.
tudy limitations. The sample size of the present study is
elatively small and does not allow definitive conclusions. The
ain difference between groups for clinical events is related to
lower rate of periprocedural myonecrosis and not a hard
linical end point such as death or ST. However, our study
ncluded a low-risk population of elective PCI, and periproce-
ural myonecrosis has been associated with adverse mid- or
ong-term prognosis including mortality (18).
cknowledgments
ssistance of our nurses’ team and technicians in executing
his study is gratefully acknowledged.
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